CTE Sessions at EANM’16

EANM’16 – CTE Session IV

October 17, 2016, 16:30 – 18:00
Nuclear Medicine Oncology beyond FDG

Chairpersons: S. Rep (Ljubljana), G. Testanera (Rozzano, Milan)

L. Ležaić (Ljubljana):
PET/CT Imaging Beyond 18F-FDG: 18F and 68Ga-labelled Tracers
D. Huić (Zagreb):
Current Status of F-18 DOPA Imaging in Neuroendocrine Tumours
G. Testanera (Milan):
PET-CT Imaging with C11 Tracers

Educational objectives:

  1. get acquainted with different oncology tracers in PET/CT investigations.
  2. get acquainted with the clinical use of PET/CT tracers for oncology investigations.
  3. get acquainted with the advantages and disadvantages of the PET/CT tracers for oncology investigations


18F-FDG is the most commonly used PET tracer of metabolism. But despite the excellent clinical efficacy of FDG in the localization of cancers, false-positive and false-negative results can cause problems in some clinical settings. Most slow growing or highly differentiated tumours have minimal glucose uptake. Some tumours are better visualized using radiolabeled amino acids or fatty acid building blocks. Using radiolabeled amino acids; 11C-acetat, 18F and 11C-cholin in early lymph node metastasis of prostate cancer has proven a diagnostic advantage. Brain tumours are preferably designed with amino acid followers (11C-metionin) as high physiological glucose consumption neurons makes FDG less useful for displaying infiltration. Into routine use are tracers constructed to target overexpressed receptors or enzymes, either for disease staging, for example 11C-metomidate in adrenal cancer, 11C-5-hydroxytryptophan and 18F-FDOPA in neuroendocrine tumours. For diagnosis in somatostatin-receptor positive neuroendocrine tumours 68Ga –DOTATATE has also proven its diagnostic value.

Key Words:

Tumours, amino acids, brain tumours, neuroendocrine tumours, prostate cancer

This website uses cookies. Learn more